Labor disputes emerge as new risk for Samsung Biologics, Celltrion

Korea’s leading biopharmaceutical firms — Samsung Biologics and Celltrion — have found themselves in unfamiliar territory facing disputes between their labor unions and management amid upbeat earnings.

The standoff between Samsung Biologics and its labor union, which began in April, appears likely to endure for some time, as both sides continue struggling to find common ground.

With the deadlock, the Samsung Biologics labor union is weighing whether it should withdraw itself from Samsung Group’s ...